Fig. 5: Boosting antibody responses by targeting antigens to Clec9a+ cDC1s. | npj Vaccines

Fig. 5: Boosting antibody responses by targeting antigens to Clec9a+ cDC1s.

From: Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials

Fig. 5

This shows how antigens coupled to anti-Clec9a antibodies are taken up by Clec9a+ cDC1s, leading to antigen presentation to CD4+ T cells via MHC class II. This interaction promotes the differentiation of Tfh cells, which are crucial for the activation of B cells. Subsequently, activated B cells produce antibodies, culminating in antibody-mediated tumor cell death. Created with Figdraw.com.

Back to article page